Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

PURPOSE: [(177)Lu]Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here, we aimed to estimate the results of PSMA-RLT in terms of response, progression-free survival (PFS), and overall survival (OS) in patie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Nucl Med Mol Imaging
Autors principals: Rasul, Sazan, Hacker, Marcus, Kretschmer-Chott, Elisabeth, Leisser, Asha, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh, Wadsak, Wolfgang, Mitterhauser, Markus, Hartenbach, Markus, Haug, Alexander R.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7005080/
https://ncbi.nlm.nih.gov/pubmed/31781834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-019-04584-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars